Currently, the most promising sleep modulating therapy in AD is the orexin antagonist suvorexant, which is used in the treatment of insomnia [304] and was approved in February 2020 for treatment of sleep disorder symptoms in AD patients. Here, HCRT is linked to sleep disorder.